Radioisotope Therapy

At Comprehensive Cancer Centers of Nevada our radiation oncologists offer optimal cancer care, and develop customized treatment plans that address each patient’s individual case and needs including Radioisotope Therapy.

Comprehensive Cancer Centers is accredited by the American College of Radiology, having earned the accreditation for eight consecutive three year terms. At Comprehensive, we offer the newest radioisotope therapies in Nevada. These are pharmaceutical treatments, have radioactivity and can be used as diagnostic and therapeutic agents. Radioisotope Therapy offered at Comprehensive Cancer Centers include Xofigo, Zevlin and Pluvicto.

Pluvicto lutetium (177Lu-PSMA) vipivotide tetraxetan is a targeted cancer treatment using lutetium-177 radiation and vipivotide tetraxetan to transport radiation directly to tumors. It is recommended for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have undergone AR pathway inhibition and taxane-based chemotherapy.

Xofigo, also known as radium-223 dichloride, is a targeted therapy for advanced prostate cancer that has spread to the bones. It works by focusing on areas with high bone activity in metastatic lesions, delivering radiation directly to cancer cells in the bones. Xofigo has shown effectiveness in prolonging overall survival and delaying bone-related issues in patients with metastatic castration-resistant prostate cancer (mCRPC), offering a valuable treatment option. Consultation with healthcare professionals is crucial to determine the best approach for individual cases.

Zevalin treats specific non-Hodgkin lymphomas with the CD20 antigen. It uses rituximab, a monoclonal antibody, and yttrium-90, a radioactive element, for targeted radiation to cancerous B cells. This dual-action method boosts treatment effectiveness by combining the antibody’s cell-killing properties with the radioactive element. Zevalin is commonly used in managing relapsed or refractory low-grade or follicular B-cell non-Hodgkin lymphoma, offering a valuable treatment option.